This article is Part 3 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 2 provided an overview of 2021 IPOs by therapeutic area.
This short article takes a deeper look into the 2021 IPOs for conventional small molecules being developed by oncology-focused companies including:
- Companies by asset class of focus and primary indication
- Lead molecules, mechanisms of action, and structures where available
- Development stage at IPO
- IPO proceeds
- A company spotlight
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
